Insulin Resistance - Pipeline Review, H2 2019

Published by Global Markets Direct on 18th November 2019 | Ref: 1464083 | This Product Is In Stock

$2000 | Single User
$4000 | Site License
$6000 | Enterprise License
$2000 | Single User
$4000 | Site License
$6000 | Enterprise License

Introduction

Insulin Resistance - Pipeline Review, H2 2019

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Insulin Resistance - Pipeline Review, H2 2019, provides an overview of the Insulin Resistance (Metabolic Disorders) pipeline landscape.

Insulin resistance (IR) is a condition in which the body's cells become resistant to the effects of insulin. This occurs when insulin levels are sufficiently high over a prolonged period of time causing the body’s own sensitivity to the hormone to be reduced. Symptoms include lethargy, hunger, difficulty concentrating and high blood pressure. Predisposing factors include obesity and hypertension.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Insulin Resistance - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Insulin Resistance (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Insulin Resistance (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Insulin Resistance and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 7 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 5 molecules, respectively.

Insulin Resistance (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Insulin Resistance (Metabolic Disorders).

- The pipeline guide reviews pipeline therapeutics for Insulin Resistance (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Insulin Resistance (Metabolic Disorders) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Insulin Resistance (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Insulin Resistance (Metabolic Disorders)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Insulin Resistance (Metabolic Disorders).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Insulin Resistance (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Insulin Resistance - Overview

Insulin Resistance - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Insulin Resistance - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Insulin Resistance - Companies Involved in Therapeutics Development

F. Hoffmann-La Roche Ltd

Lixte Biotechnology Holdings Inc

NorthSea Therapeutics BV

Pfizer Inc

Recursion Pharmaceuticals Inc

Insulin Resistance - Drug Profiles

AZP-3404 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CDN-1163 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

englerin A - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

FC-98 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Fusion Proteins to Target hOGG1 for Insulin Resistance - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

icosabutate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LB-100 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Revatio - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RG-7992 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule for Atherosclerosis and Insulin Resistance - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit AMPD2 for Hypertension and Metabolic Disorders - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules for Immunology, Metabolic Disorders and Musculoskeletal Disorders - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules for Inherited Insulin Resistance Syndrome - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SYM-401 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TM-25659 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Insulin Resistance - Dormant Projects

Insulin Resistance - Product Development Milestones

Featured News & Press Releases

Mar 21, 2019: Alize Pharma3 to present data from its AZP-3404program in syndromes of severe insulin resistance at ENDO2019

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Additional Details

Publisher

Global Markets Direct

Publisher Information

Reference

1464083 | GMDHC11419IDB

Number of Pages

48

Report Format

PDF

Related Reports

Title
Date Published
Price From
Link

Published by Global Markets Direct
15-03-2017

$2,000 USD

This report is published by Global Markets Direct

Global Markets Direct is a global market intelligence services company providing information research and analysis products and services.

Their highly qualified team of Researchers, Analysts and Solution Consultants use proprietary data sources and various tools and techniques to gather, analyse and represent the latest and the most reliable information essential for businesses to sustain a competitive edge.

Download Free Report Summary PDF

Insulin Resistance - Pipeline Review, H2 2019 | Download PDF Summary

Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

Ordering Information

Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

Accepted Card Types

Payment

Buy now using our secure payment system.